Compare SiTime Corporation (SITM) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SiTime Corporation vs GeneDx Holdings Corp — how do they compare? SiTime Corporation trades at $612.37 (market cap $19.42B), while GeneDx Holdings Corp trades at $67.33 (market cap $2.02B). The key difference: SiTime Corporation is far larger — about 9.6× GeneDx Holdings Corp's market cap, and SiTime Corporation is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold SiTime Corporation for 18 Days and GeneDx Holdings Corp for 19 Days on average.
| SITM | WGS | |
|---|---|---|
Market Cap | $19.42B | $2.02B |
Volume | 360,307 | 734,640 |
Sector | Technology | Health |
52-Week High | $901.60 | $167.51 |
52-Week Low | $252.76 | $34.51 |
Typical Hold Time | 18 Days | 19 Days |
Enterprise Value | $18.82B | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SiTime Corp (SITM) trades at $645.06, down 3.02% today but maintains strong analyst support with a $751.43 consensus price target. The stock shows bullish technical momentum with recent earnings beats and projected revenue growth from $327M in 2025 to $468M in 2026. SITM benefits from AI infrastructure demand, with Q2 2026 revenue surging 126.5% year-over-year and achieving its first GAAP profit.
Outlook remains positive with 100% analyst buy ratings and institutional accumulation, though risks include high valuation multiples (P/E 1,076, P/S 36.9) and negative 2025 net income. The company's positioning in precision timing for data centers and AI applications provides substantial growth potential, but investors should monitor execution on profitability targets and competitive pressures.
GeneDx (WGS) trades at $67.73, down 1.17% today, showing mixed signals with bearish technical indicators but strong analyst support. The company reported Q2 2026 revenue of $114.4 million, beating expectations, and returned to adjusted profitability early. However, 2026 fundamentals show concerning trends with a net loss of $106 million and negative profit margins. Recent news highlights product innovations and leadership recognition, while technical analysis indicates the stock is trading near key support at $66.
The investment outlook presents a dichotomy between strong analyst conviction (90.9% buy ratings, $81 consensus target) and challenging fundamentals. While operational improvements and genomic testing growth offer potential upside, persistent losses and negative cash flow trends create significant execution risk. The stock's current position near support levels combined with oversold RSI readings suggests potential for near-term bounce, but sustainable gains require meaningful profitability improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About SiTime Corporation
SiTime Corporation is a leading provider of MEMS-based silicon timing solutions used in various electronic applications. The company’s products, including oscillators, resonators, and clock ICs, are designed to replace traditional quartz-based timing devices, offering superior performance, reliability, and smaller size in harsh environments. SiTime's solutions are adopted across high-growth markets such as 5G, data centers, industrial IoT, and automotive, positioning the company as a key enabler for next-generation electronic systems.
Read more on SITM →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
